Heron Therapeutics | HRTX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 597.21M 34.91M 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Emergent BioSolutions USD 555.9M 242.7M 2023-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 526.79M 20.55M 2026-06
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Merck USD 15.77B 2.4B 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 180.54M 7.79M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Veracyte USD 126.36M 6.37M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06